The Current Ratio as of December 2024 (TTM) for Intra-Cellular Therapies, Inc. (ITCI) is 7.66

According to Intra-Cellular Therapies, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.66. This represents a change of 17.79% compared to the average of 6.50 of the last 4 quarters.

Intra-Cellular Therapies, Inc. (ITCI) Historical Current Ratio (quarterly & annually)

How has ITCI Current Ratio performed in the past?

The mean historical Current Ratio of Intra-Cellular Therapies, Inc. over the last ten years is 21.74. The current 7.66 Current Ratio has changed 3.42% with respect to the historical average. Over the past ten years (40 quarters), ITCI's Current Ratio was at its highest in in the December 2015 quarter at 77.15. The Current Ratio was at its lowest in in the September 2016 quarter at 3.85.

Intra-Cellular Therapies, Inc. (ITCI) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Intra-Cellular Therapies, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Intra-Cellular Therapies, Inc. (ITCI) Average Current Ratio

How has ITCI Current Ratio performed in the past?

The current Current Ratio of Intra-Cellular Therapies, Inc. (ITCI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Intra-Cellular Therapies, Inc. (ITCI) Current Ratio vs. Peers

How is ITCI’s Current Ratio compared to its peers?

Intra-Cellular Therapies, Inc.’s Current Ratio is greater than Alkermes plc (3.45), greater than Ironwood Pharmaceuticals, Inc. (3.62), greater than Deciphera Pharmaceuticals, Inc. (4.19), greater than Pacira BioSciences, Inc. (2.25), greater than Collegium Pharmaceutical, Inc. (0.97), greater than Eagle Pharmaceuticals, Inc. (1.70), greater than Neurocrine Biosciences, Inc. (4.37), less than Dynavax Technologies Corporation (13.23), greater than Amphastar Pharmaceuticals, Inc. (3.43), greater than ANI Pharmaceuticals, Inc. (2.74), greater than Cyclo Therapeutics, Inc. (0.17), greater than Amneal Pharmaceuticals, Inc. (1.38), greater than Aquestive Therapeutics, Inc. (6.37),

Build a custom stock screener for Intra-Cellular Therapies, Inc. (ITCI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Intra-Cellular Therapies, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Intra-Cellular Therapies, Inc. (ITCI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Intra-Cellular Therapies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.